ResearchEfficacy and Safety of Admilparant, an LPA₁ Antagonist, in Pulmonary Fibrosis: A Phase 2 Randomized Clinical Trial
ResearchProteomic Biomarkers of Survival in Non-Idiopathic Pulmonary Fibrosis Interstitial Lung Disease
ResearchAssociations of Interstitial Lung Disease Subtype and CT Pattern with Lung Function and Survival
ResearchAdaptive Multi-Interventional Trial Platform to Improve Patient Care for Fibrotic Interstitial Lung Diseases (REMAP-ILD)
ResearchPreacinar Arterial Dilation Mediates Outcomes of Quantitative Interstitial Abnormalities in the COPDGene Study
ResearchPulmonary Fibrosis Stakeholder Summit: A Joint NHLBI, Three Lakes Foundation, and Pulmonary Fibrosis Foundation Workshop Report
ResearchMeaningful Endpoints for Idiopathic Pulmonary Fibrosis (IPF) Clinical Trials: Emphasis on 'Feels, Functions, Survives'
ResearchZinpentraxin Alfa for Idiopathic Pulmonary Fibrosis: The Randomized Phase III STARSCAPE Trial
ResearchMolecular Endotypes of Idiopathic Pulmonary Fibrosis: A Latent Class Analysis of Two Multicenter Observational Cohorts
ResearchGenetics and Genomics of Pulmonary Fibrosis: Charting the Molecular Landscape and Shaping Precision Medicine
ResearchDesign of a Phase III, Double-Blind, Randomised, Placebo-Controlled Trial of BI 1015550 in Patients with Progressive Pulmonary Fibrosis (FIBRONEER-ILD)